BSE: RAJNISH · Healthcare · Pharmaceuticals · Market cap ₹39 Cr
· Prev close ₹0.37 · Volume 14.31 L
Company profile: not in our data yet
Net margin −4.4% (FY26)
Median of the other 5: 11.1%
Generated Return on capital is 0.5%, 6th of 6 listed peers; Abbott India is first at 44.0%.
Profit, last 4 quarters vs the 4 before: not in our data yet
Generated In FY26 revenue was +191.9% and net profit −3,734.2% on FY25.
0.3× the peers' median
Peers' median 34.3×
Generated At ₹0.38 the share is priced at 9.5× its earnings per share of ₹0.04 for the 4 quarters Dec 2025 to Sep 2026. The other 5 listed peers have a median P/E of 34.3×.
Of profit came in as cash, last 5 fiscal years: not in our data yet
100%: all profit arrived as cash
Generated Operating cash was negative in all two years FY25–26; FY26 used ₹9 cr. Total debt was ₹0 cr at the end of FY26, against a net worth of ₹103 cr.
Held by domestic funds: not in our data yet
In 1 month: not in our data yet
An earnings call transcript: not in our data yet
Scored statements from the earnings calls: none yet.
Earnings outlook Generated
In Q2 FY27 (Sep 26), net profit was +400.3% and revenue +33.8% on the year-earlier quarter; operating margin was 2.0% against 0.8%.
An earnings call transcript: not in our data yet